Benzofuran-Dihydropyridine Hybrids: A new class of potential bone anabolic agents

Publication date: Available online 17 October 2017
Source:Bioorganic & Medicinal Chemistry
Author(s): Ram K. Modukuri, Dharmendra Choudhary, Sampa Gupta, K. BhaskaraRao, SulekhaAdhikary, Tanuj Sharma, Mohammad Imran Siddiqi, Ritu Trivedi, Koneni V. Sashidhara
A series of novel benzofuran-dihydropyridine hybrids were designed by molecular hybridization approach and evaluated for bone anabolic activities. Among the screened library, ethyl 4-(7-(sec-butyl)-2-(4-methylbenzoyl)benzofuran-5-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate (compound 21) significantly enhanced the ALP production and mineralized nodule formation, which are primary requisites in the process of in-vitro osteogenesis. Oral administration of compound 21 at 10 mg.kg^-1day^-1 for two weeks led to restoration of trabecular bone microarchitecture in drill hole fracture model by significantly increasing BV/TV and Tb.N. Furthermore, histological and molecular studies showed compound 21 triggering the new bone regeneration in a drill hole defect site by increasing BMP expression. Furthermore, molecular modeling studies were performed to gain insight into the binding approach, which revealed that both benzofuran and dihydropyridine moieties are essential to show similar binding interactions to fit into the active site of BMP2 receptor, an important target of the osteogenic agents.Our results suggest that compound 21 stimulates BMP2 synthesis in osteoblast cells that promotes new bone formation (∼40%) at the fracture site which helps in shorten the healing period.

Graphical abstract

http://ift.tt/2ysEdry